321 related articles for article (PubMed ID: 26252865)
1. Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.
Ramsey LB; Janke LJ; Payton MA; Cai X; Paugh SW; Karol SE; Kamdem Kamdem L; Cheng C; Williams RT; Jeha S; Pui CH; Evans WE; Relling MV
PLoS One; 2015; 10(8):e0135134. PubMed ID: 26252865
[TBL] [Abstract][Full Text] [Related]
2. Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models.
Karol SE; Janke LJ; Panetta JC; Ramsey LB; Cai X; Payton MA; Jenkins DA; Evans WE; Relling MV
PLoS One; 2019; 14(5):e0216328. PubMed ID: 31059548
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy.
Finch ER; Janke LJ; Li L; Payton MA; Jenkins DA; Crews KR; Relling MV; Karol SE
Pediatr Blood Cancer; 2022 Apr; 69(4):e29490. PubMed ID: 34866312
[TBL] [Abstract][Full Text] [Related]
4. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial.
Mattano LA; Devidas M; Nachman JB; Sather HN; Hunger SP; Steinherz PG; Gaynon PS; Seibel NL;
Lancet Oncol; 2012 Sep; 13(9):906-15. PubMed ID: 22901620
[TBL] [Abstract][Full Text] [Related]
5. Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia.
Spenerova M; Dzubak P; Srovnal J; Radova L; Burianova R; Konecny P; Salkova S; Novak Z; Pospisilova D; Stary J; Blazek B; Hak J; Votava T; Timr P; Kaiserova E; Bubanska E; Mihal V; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Sep; 158(3):422-7. PubMed ID: 23128824
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice.
Finch ER; Payton MA; Jenkins DA; Cai X; Li L; Karol SE; Relling MV; Janke LJ
Haematologica; 2021 Aug; 106(8):2095-2101. PubMed ID: 32675219
[TBL] [Abstract][Full Text] [Related]
7. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
Mishra S; Zhang B; Groffen J; Heisterkamp N
Leukemia; 2004 Jan; 18(1):23-8. PubMed ID: 14603339
[TBL] [Abstract][Full Text] [Related]
8. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia.
te Winkel ML; Pieters R; Hop WC; de Groot-Kruseman HA; Lequin MH; van der Sluis IM; Bökkerink JP; Leeuw JA; Bruin MC; Egeler RM; Veerman AJ; van den Heuvel-Eibrink MM
J Clin Oncol; 2011 Nov; 29(31):4143-50. PubMed ID: 21947829
[TBL] [Abstract][Full Text] [Related]
9. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
Rea D; Legros L; Raffoux E; Thomas X; Turlure P; Maury S; Dupriez B; Pigneux A; Choufi B; Reman O; Stéphane D; Royer B; Vigier M; Ojeda-Uribe M; Recher C; Dombret H; Huguet F; Rousselot P; ;
Leukemia; 2006 Mar; 20(3):400-3. PubMed ID: 16437142
[TBL] [Abstract][Full Text] [Related]
10. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
Schlieben S; Borkhardt A; Reinisch I; Ritterbach J; Janssen JW; Ratei R; Schrappe M; Repp R; Zimmermann M; Kabisch H; Janka-Schaub G; Bartram CR; Ludwig WD; Riehm H; Lampert F; Harbott J
Leukemia; 1996 Jun; 10(6):957-63. PubMed ID: 8667652
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group.
Mattano LA; Sather HN; Trigg ME; Nachman JB
J Clin Oncol; 2000 Sep; 18(18):3262-72. PubMed ID: 10986059
[TBL] [Abstract][Full Text] [Related]
12. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report.
Kaspers GJ; Kardos G; Pieters R; Van Zantwijk CH; Klumper E; Hählen K; de Waal FC; van Wering ER; Veerman AJ
Leukemia; 1994 Jul; 8(7):1224-9. PubMed ID: 8035616
[TBL] [Abstract][Full Text] [Related]
13. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
14. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
[TBL] [Abstract][Full Text] [Related]
15. Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia.
den Hoed MA; Pluijm SM; te Winkel ML; de Groot-Kruseman HA; Fiocco M; Hoogerbrugge P; Leeuw JA; Bruin MC; van der Sluis IM; Bresters D; Lequin MH; Roos JC; Veerman AJ; Pieters R; van den Heuvel-Eibrink MM
Haematologica; 2015 Dec; 100(12):1564-70. PubMed ID: 26405155
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of dexamethasone before remission induction, in de novo childhood acute lymphoblastic leukemia.
López-Hernández MA; Alvarado M; De Diego J; Borbolla-Escoboza JR; Jiménez RM; Trueba E
Haematologica; 2004 Mar; 89(3):365-6. PubMed ID: 15020281
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402.
Azuma T; Tobinai K; Takeyama K; Shibata T; Hidaka M; Kurosawa M; Kasai M; Chou T; Fukushima N; Mukai K; Tsukasaki K; Shimoyama M;
Jpn J Clin Oncol; 2012 May; 42(5):394-404. PubMed ID: 22422899
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
Szymanska B; Wilczynska-Kalak U; Kang MH; Liem NL; Carol H; Boehm I; Groepper D; Reynolds CP; Stewart CF; Lock RB
PLoS One; 2012; 7(3):e33894. PubMed ID: 22479469
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
